Prognosis and prediction of response in breast cancer: The current role of the main biological markers

Cell Proliferation

Volumn 31, Issue 3-4, 1998, Pages 113-126

  Ravaioli, A ^a,c   Bagli, L ^b   Zucchini, A ^b   Monti, F ^a  

^a Azienda USL Rimini   (Italy)

^b ISTITUTO ONCOLOGICO ROMAGNOLO   (Italy)

^c Ospedale Infermi   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; BIOLOGICAL MARKER; CARBOPLATIN; CISPLATIN; CYCLINE; CYCLOPHOSPHAMIDE; DNA; DOXORUBICIN; EPIRUBICIN; ESTROGEN RECEPTOR; ETOPOSIDE; FLUOROURACIL; FOLINIC ACID; GOSERELIN; MEGESTROL ACETATE; METHOTREXATE; MITOMYCIN C; MITOXANTRONE; MONOCLONAL ANTIBODY KI 67; NAVELBINE; PREDNISOLONE; PROGESTERONE RECEPTOR; PROTEIN BCL 2; PROTEIN P53; TAMOXIFEN; THYMIDINE; TUMOR MARKER; UROKINASE;

ADJUVANT CHEMOTHERAPY; BREAST CANCER; CELL CYCLE S PHASE; CELL PROLIFERATION; CHEMOTHERAPY; FLOW CYTOMETRY; GENE EXPRESSION; HORMONAL THERAPY; HUMAN; IMMUNOHISTOCHEMISTRY; LABELING INDEX; MENOPAUSE; MULTIVARIATE ANALYSIS; ONCOGENE NEU; PLOIDY; REVIEW; SURVIVAL RATE; TUMOR RESISTANCE;

EID: 0031764342     PISSN: 09607722     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2184.1998.tb01190.x     Document Type: Review

References (96)

1. AAS T, BREESON AL, GEISLER S. (1996) Specific p53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients. Nat. Med. 2, 811.
2. ALLRED DC, CLARK GM, TANDON AK et al. (1992) Her-2/neu in node-negative breast cancer: prognostic significance of overexpression influenced by the presence of in situ carcinoma. J. Clin. Oncol. 10, 599.
3. AMADORI D, VOLPI A, MALTONI R et al. (1997) Cell proliferation as a predictor of response to chemotherapy in metastatic breast cancer: A prospective study. Breast Cancer Res. Treat. 43, 7.
4. AMERICAN SOCIETY OF CLINICAL ONCOLOGY. (1996) Clinical practice guidelines for the use of tumor markers in breast and colorectal cancer. J. Clin. Oncol. 14, 2843.
5. ARCHER SG, ELIOPOLOUS A, SPANDIDOS D et al. (1995) Expression of ras, p53 and c-erbB-2 in advanced breast cancer and response to first line hormonal therapy. Br. J. Cancer 72, 1256.
6. ARRIAGADA R, RUTQVIST LE, SKOOG L et al. (1992) Prognostic factors and natural history in lymph node-negative breast cancer patients. Breast Cancer Res. Treat. 21, 101.
7. BALSLEV I, CHRISTENSEN IJ, RASMUSSEN BB et al. (1994) Flow cytometric DNA ploidy defines patients with poor prognosis in node-negative breast cancer. Int. J. Cancer 56 (1), 16.
8. BERGERS E, BAAK JPA, VAN DIEST PJ et al. (1997) Prognostic implications of different cell cycle analysis models of flow cytometric DNA histograms of 1,301 breast cancer patients: results from the multicenter morphometric mammary carcinoma project (MMMCP). Int. J. Cancer 74, 260.
9. BIANCHI S, CALZOLARI A, VEZZOSI V et al. (1997). Lack of prognostic value of p53 protein expression in node-negative breast cancer. Tumori 83, 699.
10. BIANCHI S, PAGLIERANI M, ZAMPI G et al. (1993) Prognostic significance of c-erbB-2 expression in node negative breast cancer. Br. J. Cancer 67, 625.
11. BONETTI A, ZANINLLI M, RODELLA S et al. (1996) Tumor proliferative activity and response to first-line chemotherapy in advanced breast carcinoma. Breast Cancer Res. Treat. 38, 289.
12. BORG A, LENNERSTRAND J, STENMARK-ASKMALM M et al. (1995) Prognostic significance of p53 overexpression in primary breast cancer; A novel luminometric imunoassay applicable on steroid receptor cytosols. Br. J. Cancer 71, 1013.
13. BOSARI S, LEE AK, TAHAN SR et al. (1992) DNA flow cytometric analysis and prognosis of axillary lymph node-negative breast carcinoma. Cancer 70, 1943.
14. BOUZUBAR N, WALKER KJ, GRIFFITHS K et al. (1989) Ki-67 immunostaining in primary breast cancer: pathological and clinical associations. Br. J. Cancer 59, 943.
15. BREAST CANCER TRIALS COMMITTEE. (1987) Adjuvant tamoxifen in the management of operable breast cancer: The Scottish Trial. Lancet 2, 171.
16. CARLOMAGNO C, PERRONE F, GALLO C et al. (1996) C-erbB2 overexpression decreases the benefit of adjuvant tamoxifen in early-stage breast cancer without axillary lymph node metastases. J. Clin. Oncol. 14, 270.
17. CLARK GM, DRESSER LG, OWENS MA et al. (1989) Prediction of relapse or survival in patients with node-negative breast cancer by DNA flow cytometry. N. Engl. J. Med. 320, 627.
18. CUEVAS E, JONES DB, WRIGHT DH et al. (1993) Immunohistochemical detection of tumor growth fraction (Ki-67 antigen) in formalin-fixed and routinely processed tissues. J. Pathol. 169, 477.
19. DETTMAR P, HARBECK N, THOMSSEN C et al. (1997) Prognostic impact of proliferation-associated factors MIB1 (Ki-67) and S-phase in node-negative breast cancer Br. J. Cancer 75, 1525.
20. DUFFY MJ, DUGGAN C, MAGUIRE T et al. (1996) Urokinase plasminogen activator as a predictor of aggressive disease in breast cancer. Enzyme Protein 49, 85.
21. DUGGAN C, KENNEDY S, KRAMER MD et al. (1997) Plasminogen activator inhibitor type 2 in breast cancer. Br. J. Cancer 76, 622.
22. EARLY BREAST CANCER TRIALISTS' COLLABORATIVE GROUP. (1988) Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer. N. Engl. J. Med. 319, 1681.
23. EARLY BREAST CANCER TRIALISTS' COLLABORATIVE GROUP. (1992) Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. Lancet 339, 71.
24. ELLEDGE RM, GREEN S, HOWES L et al. (1997) Bcl-2, p53, and response to tamoxifen in estrogen receptor-positive metastatic breast cancer. J. Clin. Oncol. 15, 1916.
25. FERNO M, BALDETORP B, BENDAHL PO et al. (1995) Recurrence-free survival in breast cancer improved by adjuvant tamoxifen especially for progesterone receptor positive tumors with a high proliferation. Breast Cancer Res. Treat. 36, 23.
26. FERNO M, BENDAHL PO, BORG A et al. (1996) Urokinase plasminogen activator, a strong independent prognostic factor in breast cancer, analysed in steroid receptor cytosols with a luminometric immunoassay. Eur. J. Cancer 32A, 793.
27. FISHER B, REDMOND C, BROWN A et al. (1983) Influence of tumor estrogen and progesterone receptor levels on the response to tamoxifen and chemotherapy in primary breast cancer J. Clin. Oncol. 4, 227.
28. FISHER B, REDMOND C, FISHER ER et al. (1988) Relative worth of estrogen or progesterone receptor and pathologic characteristics of differentiation as indicators of prognosis in node-negative breast cancer patients: Findings from National Surgical Adjuvant Breast and Bowel Project protocol. B-06. J. Clin. Oncol. 6, 1076.
29. FOEKENS JA, BUESSECKER F, PETERS HA et al. (1995a) Plasminogen activator inhibitor-2: prognostic relevance in 1012 patients with primary breast cancer. Cancer Res. 55, 1423.
30. FOEKENS JA, LOOK MP, PETERS HA et al. (1995b) Urokinase-type plasminogen activator and its inhibitor PAI-1. predictors of poor response to tamoxifen therapy in recurrent breast cancer. J. Natl. Cancer Inst. 87, 751.
31. FORMENTI SC, LENZ J, DUNNINGTON G et al. (1996) Initial p53 status as potential predictor for pathological response to the combination of 5FU and radiotherapy in locally advanced breast cancer. Proc. Ann. Meet. Am. Soc. Clin. Oncol. 15, A174.
32. FRESNO R, MOLINA R, PEREZ MJ et al. (1997) P53 expression of independent predictive value in lymph node-negative breast carcinoma. Eur. J. Cancer 33, 1268.
33. GARDIN G, ALAMA A, ROSSO R et al. (1994) Relationship of variation in tumor cell kinetics induced by primary chemotherapy to tumor regression and prognosis in locally advanced breast cancer. Breast Cancer Res. Treat. 32, 311.
34. GASPARINI G, BARBARESCHI M, DOGLIONI C et al. (1995) Expression of Bcl-2 protein predicts efficacy of adjuvant treatments in operable node-positive breast cancer. Clin. Cancer Res. 1, 189.
35. GILLET C, FANTL V, SMITH R et al. (1994) Amplification and overexpression of cyclin D1 in breast cancer detected by immunohistochemical staining. Cancer Res. 54, 1812.
36. GILLET C, SMITH P, GREGORY W et al. (1996) Cyclin D1 and prognosis in breast cancer. Int. J. Cancer 69, 92.
37. GRONDAHL-HANSEN J, HILSENBECK SJ, CHRISTENSEN IJ et al. (1997) Prognostic significance of PAI-1 and uPA in cytosolic extracts obtained from node-positive breast cancer patients. Breast Cancer Res. Treat. 43, 153.
38. GRONDAHL-HANSEN J, PETERS HA, VAN PUTTEN WL et al. (1995) Prognostic significance of the receptor for urokinase plasminogen activator in breast cancer. Clin. Cancer Res. 1, 1079.
39. GUSTERSON BA, GELBER RD, GOLHIRSCH A et al. (1992) Prognostic importance of c-erbE-2 expression in breast cancer. J. Clin. Oncol. 10, 1049.
40. HAYES DF. (1997) When is a tumor marker ready for prime time? The tumor marker utility grading scale. In: Perry MC, ed. Thirty-third Annual Meeting. American Society of Clinical Oncology. Alexandria VA: Educational Book, 206.
41. HIETANEN P, BLOMQVIST C, VASENIUS V-M, NISKANEN E, FRANSSILA K, NORDLING S. (1995) Do DNA ploidy and S-phase fraction in primary tumor predict the response to chemotherapy in metastatic breast cancer? Br. J. Cancer 71, 1029.
42. HILF R, FELDSTEIN ML, GIBSON SL et al. (1980) The relative importance of estrogen receptor analysis as a prognostic factor for recurrence or response to chemotherapy in women with breast cancer. Cancer 45, 1993.
43. HOSKINS K, WEBER BL. (1994) The biology of breast cancer. Curr. Opin. Oncol. 6, 554.
44. JANSSON T, INGANAS M, SJOGREN S et al. (1995) P53 status predicts survival in breast cancer patients treated with or without postoperative radiotherapy: a novel hypothesis based on clinical findings. J. Clin. Oncol. 13, 2745.
45. JOENSUU H, PYLKKANEN L, TOIKKANEN S. (1994) Bcl-2 protein expression and long-term survival in breast cancer. Am. J. Pathol. 145, 1191.
46. KALLIONIEMI OP, HOLLI K, VISAKORPI T et al. (1991) Association of c-erbB-2 protein overexpression with high rate of cell proliferation, increased risk of visceral metastasis and poor long-term survival in breast cancer. Int. J. Cancer 49, 650.
47. KING RJ. (1993) Estrogen and progestin effects in human breast carcinogenesis. Breast Cancer Res. Treat. 27, 3.
48. KOSAKA A, SUMIYOSHI K. (1995) Fluctuations of plasminogen activator system in patients with breast cancer (1st report) - especially the effects of preoperative administration of 5′-deoxy-5-fluorouridine (5′-dfur) and pyrimidine nucleoside phosphorylase (pynpase) activity. Can. J. Infectious Dis. 6C, 226.
49. LEITZEL K, TERAMOTO Y, KONRAD K et al. (1995) Elevated serum c-erbR-2 antigen levels and decreased response to hormone therapy of breast cancer. J. Clin. Oncol. 13, 1129.
50. LIPPONEN P, JI H, AALTOMAA S, SYRJANEN S, SYRJANEN K. (1993) P53 protein expression in breast cancer as related to histopathological characteristics and prognosis Int. J. Cancer 55 (1), 51.
51. LOVEKIN C, ELLIS IO, LOCKER A et al. (1991) c-erbB-2 oncoprotein expression in primary and advanced breast cancer. Br. J. Cancer 63, 439.
52. LOWE SW, RULEY HE, JACKS T et al. (1993) P53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 74, 957.
53. LUPU R, LIPPMAN ME. (1993) The role of erb-B2 signal transduction pathways in human breast cancer. Breast Cancer Res. Treat. 27, 83.
54. MAKRIS A, POWLES TJ, DOWSETT M et al. (1997) Prediction of response to neoadjuvant chemoendocrine therapy in primary breast carcinomas. Clin. Cancer Res. 3, 593.
55. MCINTOSH GG, THOMAS MD, ANDERSON JJ, ANGUS B, HORNE CH. (1995) Determination of the prognostic value of cyclin D1 overexpression in breast cancer. Oncogene 11, 885.
56. MERKEL DE, WINCHESTER DJ, GOLDSCHIMD RA et al. (1993) DNA flow cytometry and pathologic grading prognostic guides in axillary lymph node negative breast cancer. Cancer 72, 1926.
57. MICHALIDES R, HAGEMAN P, VAN TINTEREN H et al. (1996) A clinicopathological study on overexpression of cyclin D1 and of p53 in a series of 248 patients with operable breast cancer. Br. J. Cancer 73, 728.
58. MURPHY LC. (1995) Mechanisms associated with the progression of breast cancer from hormone dependence to independence. The Pezcoller Foundation J. 6, 6.
59. MUSS HB, THOR AD, BERRY DA et al. (1994) C-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. N. Engl. J. Med. 330, 1260.
60. NIELSEN NH, ARNERLOV C, EMDIN SO et al. (1996) Cyclin E overexpression, a negative prognostic factor in breast cancer with strong correlation to oestrogen receptor status. Br. J. Cancer 74, 874.
61. O'REILLY SM, CAMPLEJOHN RS, RUBENS RD et al. (1992) DNA flow cytometry and response to preoperative chemotherapy from primary breast cancer. Eur. J. Cancer 28, 681.
62. PARADISO A, TOMMASI S, MANGIA A et al. (1990) Tumor proliferate activity, progesterone receptor status, estrogen receptor level and clinical outcome of estrogen receptor-positive advanced breast cancer. Cancer Res. 50, 2958.
63. PELOSIO P, BARDARESCHI M, BONOLDI E et al. (1996) Clinical significance of cyclin D1 expression in patients with node-positive breast carcinoma treated with adjuvant therapy. Ann. Oncol. 7, 695.
64. PFISTERER J, KOMMOSS F, SAUERBREI W et al. (1995) DNA flow cytometry in node-positive breast cancer Prognostic value and correlation with morphologic and clinical factors. Anal. Quant. Cytol. Histol. 17, 406.
65. PIERGA JY, LAINE-BIDRON C, BEUZEBOC P et al. (1997) Plasminogen activator inhibitor-1 (PAI-1) is not related to response to neoadjuvant chemotherapy in breast cancer. Br. J. Cancer 76, 537.
66. PIERGA JY, LEROYER A, VIEHL P et al. (1996) Long term prognostic value of growth fraction determination by Ki-67 immunostaining in primary operable breast cancer. Breast Cancer Res. Treat. 37, 57.
67. PRESS MF, PIKE MC, CHAZIN VR et al. (1994) Her-2/neu expression in node-negative breast cancer: direct tissue quantitation by computerized image analysis and association of overexpression with increased risk of recurrent disease. Cancer Res. 53, 4960.
68. RAEMAEKERS JMM, BEEX LVAM, PIETERS GFFM et al. (1987) Progesterone receptor activity and relapse-free survival in patients with primary breast cancer. The role of adjuvant chemotherapy. Br. Cancer Res. Treat. 9, 191.
69. RAILO M, LUNDIN J, HAGLUND CAJ et al. (1997) Ki-67, P53 ER-receptors, ploidy and s-phase as prognostic factors in t1 node negative breast cancer. Acta Oncol. 36, 369.
70. RAVDIN PM. (1997) Prognostic factors in breast cancer. In: Perry MC, ed. Thirty-third Annual Meeting. American Society of Clinical Oncology. Alexandria VA: Educational Book, 217.
71. RAVDIN PM, GREEN S, DORR TM et al. (1992) Prognostic significance of progesterone receptor levels in estrogen receptor-positive patients with metastatic breast cancer treated with tamoxifen: Results of a prospective Southwest Oncology Group study. J. Clin. Oncol. 10, 1284.
72. REMVIKOS Y, JOUVE M, BEUZEBOC P et al. (1993) Cell cycle modifications of breast cancer during neoadjuvant chemotherapy: a flow cytometry study on fine needle aspirates. Eur. J. Cancer 29A, 1943.
73. SCHIMMELPENNING H, ERIKSSON ET, ZETTEMBERG A, AVER GU. (1994) Association of immunohistochemical p53 tumor suppressor gene protein overexpression with prognosis in highly proliferative human mammary adenocarcinomas. World J. Surg. 18, 827.
74. SCOTTISH CANCER TRIALS BREAST GROUP ICRF BREAST UNIT, GUY'S LONDON. (1993) Adjuvant ovarian ablation vs. CMF chemotherapy in premenopausal women with pathological stage II breast carcinoma: the Scottish Trial. Lancet 341, 1293.
75. SILVESTRINI R, BENINI E, VENERONI S et al. (1996b) P53 and Bcl-2 expression correlates with clinical outcome in a series of node-positive breast cancer patients. J. Clin. Oncol. 14 (5), 1604.
76. SILVESTRINI R, DAIDONE MG, BENINI E et al. (1996a) Validation of p53 accumulation as a predictor of distant metastasis at 10 years of follow-up in 1400 node-negative breast cancers. Clin. Cancer Res. 2, 2007.
77. SILVESTRINI R, DAIDONE MG, DEL BINO G et al. (1993b) Prognostic significance of proliferative activity and ploidy in node-negative breast cancer. Ann. Oncol. 4, 213.
78. SILVESTRINI R, DAIDONE MG, LUISI A et al. (1995) Biologic and clinicopathologic factors as indicators of specific relapse types in node-negative breast cancer. J. Clin. Oncol. 13, 697.
79. 3H-thymidine labelling index. Int. J. Cancer 74, 122.
80. SILVESTRINI R, DAIDONE MG, MASTORE M et al. (1993a) Cell kinetics as a predictive factor in node-positive breast cancer treated with adjuvant hormone therapy. J. Clin. Onc. 11, 1150.
81. SILVESTRINI R, DAIDONE MG, VALAGUSSA P et al. (1987) Cell kinetics as a prognostic marker in locally advanced breast cancer. Cancer Treat. Rep. 71, 375.
82. 3H-thymidine-labeling index as a prognostic indicator in node-positive breast cancer. J. Clin. Oncol. 8, 1321.
83. SILVESTRINI R, VENERONI S, BENINI E et al. (1997a) Expression of p53, glutathione s-transferase-π and bcl-2, proteins and benefit from adjuvant radiotherapy in breast cancer. J. Natl. Cancer Inst. 89, 639.
84. SILVESTRINI R, VENERONI S, DAIDONE MG et al. (1994) The Bcl-2 protein: a prognostic indicator strongly related to p53 protein in lymph node-negative breast cancer patient J. Natl. Cancer Inst. 86, 499.
85. STAL O, ASMALM MS, WINGREN S et al. (1995) P53 expression and the result of adjuvant therapy of breast cancer. Acta Oncologica 34, 767.
86. STEWART HJ. (1992) The Scottish trial of adjuvant tamoxifen in node-negative breast cancer. Monograf. J. Natl. Cancer Inst. Mono 11, 117.
87. SULKES A, LIVINGSTON RB, MURPHY WK. (1979) Tritiated thymidine labeling index and response in human breast cancer. J. Natl. Cancer Inst. 62, 513.
88. TEIXEIRA C, REED JC, PRATT MAC. (1995) Estrogen promotes chemotherapeutic drug resistance by a mechanism involving Bcl-2 proto-oncogene expression in human breast cancer cells. Cancer Res. 55, 3902.
89. THOR AD, MOORE IIDH, EDGERTON SM et al. (1992) Accumulation of p53 tumor suppressor gene protein: an independent marker of prognosis in breast cancer. J. Natl. Cancer Inst. 84, 845.
90. TOIKKANEN S, HELIN H, ISOLA J et al. (1992) Prognostic significance of HER-2 oncoprotein expression in breast cancer: a 30-year follow up. J. Clin. Oncol. 10, 1044.
91. VAN SLOOTEN HJ, CLAHSEN PC, VAN DIERENDOCK JH et al. (1996) Expression of Bcl-2 in node-negative breast cancer is associated with various prognostic factors, but does not predict response to one course of perioperative chemotherapy. Br. J. Cancer 74, 78.
92. WALTON MI, WHYSONG D, O'CONNOR PM et al. (1993) Constitutive expression of human bcl-2 modulates nitrogen mustard, camptothecin induced apoptosis. Cancer Res. 53, 1853.
93. WEIDNER N, MOORE DH, VARTANIAN R et al. (1994) Correlation of Ki-67 antigen expression with mitotic figure index and tumor grade in breast carcinomas using the novel 'paraffin' reactive MIB1 antibody. Hum. Pathol. 25, 337.
94. WITZIG TE, INGLE JN, CHA SS et al. (1994) DNA ploidy and the percentage of cell in S-phase as a prognostic factors for women with lymph node negative breast cancer. Cancer 74, 1952.
95. WITZIG TE, JAMES NI, SCHAID DJ et al. (1993) DNA ploidy and percent s-phase as prognostic factors in node-positive breast cancer: results from patients enrolled in two prospective randomized trials. J. Clin. Oncol. 11, 351.
96. ZHOU P, JIANG W, WEGHORST CM et al. (1996) Overexpression of cyclin D1 enhances gene amplification. Cancer Res. 56, 36.